Cytokine profiles in acute myeloid leukemia patients at diagnosis: Survival is inversely correlated with IL-6 and directly correlated with IL-10 levels

Cytokine

Volumn 61, Issue 3, 2013, Pages 885-891

  Sanchez Correa, Beatriz ^a   Bergua, Juan M ^b   Campos, Carmen ^c   Gayoso, Inmaculada ^c   Arcos, Maria Jose ^b   Bañas, Helena ^b   Morgado, Sara ^a   Casado, Javier G ^a,d   Solana, Rafael ^c   Tarazona, Raquel ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^c UNIVERSITY OF CÓRDOBA   (Spain)

^d JESÚS USÓN MINIMALLY INVASIVE SURGERY CENTRE   (Spain)

Author keywords

Acute myeloid Leukemia; IL 10; IL 6; Pro inflammatory cytokines; Survival

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVENT FREE SURVIVAL; FEMALE; HUMAN; INFLAMMATION; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BLAST CRISIS; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875375314     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.12.023     Document Type: Article

References (52)

1. Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
2. Estey E.H. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012, 87:89-99.
3. Fauriat C., Just-Landi S., Mallet F., Arnoulet C., Sainty D., Olive D., et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 2007, 109:323-330.
4. Sanchez-Correa B., Morgado S., Gayoso I., Bergua J.M., Casado J.G., Arcos M.J., et al. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother 2011, 60:1195-1205.
5. Sanchez-Correa B., Gayoso I., Bergua J.M., Casado J.G., Morgado S., Solana R., et al. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol 2012, 90:109-115.
6. Shenghui Z., Yixiang H., Jianbo W., Kang Y., Laixi B., Yan Z., et al. Elevated frequencies of CD4(+) CD25(+) CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer 2011, 129:1373-1381.
7. Le Dieu R., Taussig D.C., Ramsay A.G., Mitter R., Miraki-Moud F., Fatah R., et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 2009, 114:3909-3916.
8. Chan L., Hardwick N.R., Guinn B.A., Darling D., Gaken J., Galea-Lauri J., et al. An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia. Cancer Immunol Immunother 2006, 55:1017-1024.
9. Panju A.H., Danesh A., Minden M.D., Kelvin D.J., Alibhai S.M. Associations between quality of life, fatigue, and cytokine levels in patients aged 50+ with acute myeloid leukemia. Support Care Cancer 2009, 17:539-546.
10. Panteli K.E., Hatzimichael E.C., Bouranta P.K., Katsaraki A., Seferiadis K., Stebbing J., et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Brit J Haematol 2005, 130:709-715.
11. Van Etten R.A. Aberrant cytokine signaling in leukemia. Oncogene 2007, 26:6738-6749.
12. Park H.H., Kim M., Lee B.H., Lim J., Kim Y., Lee E.J., et al. Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia. Ann Clin Lab Sci 2006, 36:7-15.
13. Kornblau S.M., McCue D., Singh N., Chen W., Estrov Z., Coombes K.R. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010, 116:4251-4261.
14. Tsimberidou A.M., Estey E., Wen S., Pierce S., Kantarjian H., Albitar M., et al. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008, 113:1605-1613.
15. Moller B., Villiger P.M. Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin Immunopathol 2006, 27:391-408.
16. Sugiyama H., Inoue K., Ogawa H., Yamagami T., Soma T., Miyake S., et al. The expression of IL-6 and its related genes in acute leukemia. Leuk Lymphoma 1996, 21:49-52.
17. Beauchemin V., Villeneuve L., Rodriguez-Cimadevilla J.C., Rajotte D., Kenney J.S., Clark S.C., et al. Interleukin-6 production by the blast cells of acute myeloblastic leukemia: regulation by endogenous interleukin-1 and biological implications. J Cell Physiol 1991, 148:353-361.
18. Apte R.N., Dotan S., Elkabets M., White M.R., Reich E., Carmi Y., et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006, 25:387-408.
19. Elkabets M., Ribeiro V.S., Dinarello C.A., Ostrand-Rosenberg S., Di Santo J.P., Apte R.N., et al. IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 2010, 40:3347-3357.
20. Kurzrock R. Cytokine deregulation in cancer. Biomed Pharmacother 2001, 55:543-547.
21. Saily M., Koistinen P., Savolainen E.R. The soluble form of interleukin-6 receptor modulates cell proliferation by acute myeloblastic leukemia blast cells. Ann Hematol 1999, 78:173-179.
22. Steensberg A., Fischer C.P., Keller C., Moller K., Pedersen B.K. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 2003, 285:E433-E437.
23. You M., Flick L.M., Yu D., Feng G.S. Modulation of the nuclear factor kappa B pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor. J Exp Med 2001, 193:101-110.
24. Kimura A., Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010, 40:1830-1835.
25. Stenvinkel P., Ketteler M., Johnson R.J., Lindholm B., Pecoits-Filho R., Riella M., et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 2005, 67:1216-1233.
26. de Gonzalo-Calvo D., de Luxan-Delgado B., Martinez-Camblor P., Rodriguez-Gonzalez S., Garcia-Macia M., Suarez F.M., et al. Chronic inflammation as predictor of 1-year hospitalization and mortality in elderly population. Eur J Clin Invest 2012, 10-2362.
27. Alvarez-Rodriguez L., Lopez-Hoyos M., Munoz-Cacho P., Martinez-Taboada V.M. Aging is associated with circulating cytokine dysregulation. Cell Immunol 2012, 273:124-132.
28. Larbi A., Franceschi C., Mazzatti D., Solana R., Wikby A., Pawelec G. Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda) 2008, 23:64-74.
29. Palmeri M., Misiano G., Malaguarnera M., Forte G.I., Vaccarino L., Milano S., et al. Cytokine serum profile in a group of sicilian nonagenarians. J Immunoassay Immunochem 2012, 33:82-90.
30. Candore G., Caruso C., Colonna-Romano G. Inflammation, genetic background and longevity. Biogerontology 2010, 11:565-573.
31. Naumova E., Ivanova M., Pawelec G. Immunogenetics of ageing. Int J Immunogenet 2011, 38:373-381.
32. Camporeale A., Poli V. IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?. Front Biosci 2012, 17:2306-2326.
33. Wu C., Wang S., Wang F., Chen Q., Peng S., Zhang Y., et al. Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol 2009, 158:199-204.
34. Ryningen A., Wergeland L., Glenjen N., Gjertsen B.T., Bruserud O. In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leuk Res 2005, 29:185-196.
35. Hsu H.C., Lee Y.M., Tsai W.H., Jiang M.L., Ho C.H., Ho C.K., et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology 2002, 63:64-69.
36. El-Maksoud N.A., Halla M.R., El-Latif M.M., Abdalla S.H. Prognostic Impact of elevated serum hyaluronic acid, ferritin and interleukin-6 in patients with acute myeloid leukemia. J Am Sci 2010, 6:532-541.
37. Nielsen A.R., Plomgaard P., Krabbe K.S., Johansen J.S., Pedersen B.K. IL-6, but not TNF-alpha, increases plasma YKL-40 in human subjects. Cytokine 2011, 55:152-155.
38. Bergmann O.J., Johansen J.S., Klausen T.W., Mylin A.K., Kristensen J.S., Kjeldsen E., et al. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin Cancer Res 2005, 11:8644-8652.
39. Asano Y., Shibata S., Kobayashi S., Okamura S., Niho Y. Interleukin-10 inhibits the autocrine growth of leukemic blast cells from patients with acute myeloblastic leukemia. Int J Hematol 1997, 66:445-450.
40. Mocellin S., Marincola F.M., Young H.A. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005, 78:1043-1051.
41. Zamarron B.F., Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011, 7:651-658.
42. Reuter S., Gupta S.C., Chaturvedi M.M., Aggarwal B.B. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radical Biol Med 2010, 49:1603-1616.
43. Szlosarek P., Charles K.A., Balkwill F.R. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006, 42:745-750.
44. Bruunsgaard H., Pedersen B.K. Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am 2003, 23:15-39.
45. Aguayo A., Kantarjian H., Manshouri T., Gidel C., Estey E., Thomas D., et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000, 96:2240-2245.
46. Pasche B. Role of transforming growth factor beta in cancer. J Cell Physiol 2001, 186:153-168.
47. Hu X., Cui D., Moscinski L.C., Zhang X., Maccachero V., Zuckerman K.S. TGFbeta regulates the expression and activities of G2 checkpoint kinases in human myeloid leukemia cells. Cytokine 2007, 37:155-162.
48. Szczepanski M.J., Szajnik M., Czystowska M., Mandapathil M., Strauss L., Welsh A., et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009, 15:3325-3332.
49. Colombo M.P., Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002, 13:155-168.
50. Ferretti E., Di C.E., Cocco C., Ribatti D., Sorrentino C., Ognio E., et al. Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol Lett 2010, 133:99-105.
51. Li Z., Chen L., Qin Z. Paradoxical roles of IL-4 in tumor immunity. Cell Mol Immunol 2009, 6:415-422.
52. Wrobel T., Mazur G., Jazwiec B., Kuliczkowski K. Interleukin-17 in acute myeloid leukemia. J Cell Mol Med 2003, 7:472-474.